TreatSMA

Skiggle’s round-the-clock SOS emergency alert system

Published:

Updated:

Skiggle offer support for disabled individuals, by funding and operating a unique round-the-clock SOS emergency alert service. This provides a place for people to turn to if they urgently need a piece of equipment, feed, or disability care product.

All you need to do is sign up to join the Skiggle community and if someone within your geographical area puts out a call for help, you will be alerted and could provide a lifeline for another person in the disabled world. You never know when you might need someone’s help yourself.

Skiggle also runs an online marketplace where people can safely give away and distribute
disability care products and equipment and a Facebook forum where people can join our
friendly community for daily help, support and advice.

You can find more information here.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more